Rectal Cancer Super Session- “What’s New for You”

Sunday, June 2, 2024

10:15 AM – 11:00 AM ET, USA

Location: Baltimore Convention Center, Hall A

Super Session Moderator(s)

Radhika Smith, MD

Saint Louis, MO

All relevant financial disclosures have been managed and will be listed below.
This individual has no financial relationships with ineligible companies.
Jose Guillem, MD

Professor of surgery
UNC- Chapel Hill
UNC-Chapel Hill
Chapel hill, North Carolina, United States

All relevant financial disclosures have been managed and will be listed below.
This individual has no relevant relationships with ineligible companies.

CME Credit: 0.75
Self-Assessment Credit: 0.75
Contact Hours: 0.75

Polling will be utilized during this symposium.

This symposium is designed to update the practicing colorectal on recent and upcoming rectal cancer trials that have the potential to alter practice patterns.

Learning Objectives:

Upon completion of this activity, participants should be able to:

Recognize the role of total neoadjuvant therapy to aid in organ prevention.
Identify special considerations for patients under the age of 50 with rectal cancer.
Verbalize the benefit of preoperative chemotherapy in high-risk locally advanced rectal cancer.

Presentations:

10:15 AM – 11:00 AM ET, USA

Rectal Cancer Super Session- “What’s New for You”
Super Session Moderator: Radhika Smith, MD
Super Session Moderator: Jose Guillem, MD – UNC- Chapel Hill
10:15 AM – 10:17 AM ET, USA

Introduction
Super Session Speaker: Radhika Smith, MD
Super Session Speaker: Jose Guillem, MD – UNC- Chapel Hill
10:17 AM – 10:26 AM ET, USA

Review of “ Neoadjuvant Chemotherapy with FOLFIRINOX and Preoperative Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-label, Phase 3 Trial” and Short-course Radiotherapy Followed by Chemotherapy Before Total Mesorectal Excision (TME) versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-label, Phase 3 Trial
Super Session Speaker: Thomas E. Read, MD – University of Florida
10:26 AM – 10:35 AM ET, USA

Review of “organ Preservation in Rectal Adenocarcinoma: A Phase II Randomized Controlled Trial Evaluating 3-year Disease-free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Nonoperative Management”
Super Session Speaker: Julio Garcia-Aguilar, MD, PhD (he/him/his) – Memorial Sloan Kettering Cancer Center
10:35 AM – 10:44 AM ET, USA

Review of “PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery”
Super Session Speaker: Martin Weiser, MD – Memorial Sloan Kettering Cancer Center
10:44 AM – 10:53 AM ET, USA

Review of Young Onset Colorectal Cancer with a Focus on Management an Treatment Considerations
Super Session Speaker: Y. Nancy You, MD, MHSc – University of Texas MD Anderson Cancer Center
10:53 AM – 11:00 AM ET, USA

Question and Answer